Cellivate Technologies

The firm follows a business-to-business (B2B) model, providing solutions that address significant challenges in cell culture and biomanufacturing. Its client base includes companies in the cultivated meat, cosmetics, skincare, and cultivated leather industries. Revenue is generated through the sale of both standardized and customized products, with plans to license its technology and offer technical services in a second phase. Currently, the primary revenue stream comes from collaborations with skincare partners. Cellivate has demonstrated early market traction, with orders and interest that have exceeded its production capacity.

Cellivate Technologies offers a portfolio of products designed to enhance the efficiency and reduce the cost of cell growth. Its flagship offerings include advanced microcarriers for scaling up cell production and a novel cell-based serum, branded as Booster, which is designed as a xeno-free replacement for Fetal Bovine Serum (FBS). This addresses a critical market need, as FBS is an expensive and ethically controversial component in cell culture. The company's patented nanotechnology utilizes different oxide chemistries to improve cell adhesion and accelerate growth. This core technology enables Cellivate to offer solutions that maintain cell growth consistency, limit batch variability, and support regulatory alignment for its clients. The company has successfully raised capital through multiple funding rounds, including a notable $1 million seed round in August 2024 and significant funding secured through the business reality show, The Big Spark.